Promising gene therapies pose million-dollar conundrum.
Erika
E
Check Hayden
D000627:Aminophenols / Q000191:economics; D000755:Anemia, Sickle Cell / Q000191:economics / Q000235:genetics / Q000628:therapy; D000911:Antibodies, Monoclonal / Q000191:economics; D061067:Antibodies, Monoclonal, Humanized; D001709:Biotechnology / Q000191:economics / Q000639:trends; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000191:economics; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics; D015316:Genetic Therapy / Q000191:economics* / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D007348:Insurance, Health / Q000191:economics; D009369:Neoplasms / Q000191:economics / Q000235:genetics / Q000276:immunology / Q000628:therapy; D015363:Quinolones / Q000191:economics; D000069474:Sofosbuvir / Q000191:economics
D000627:Aminophenols; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015363:Quinolones; C545203:ivacaftor; C577155:evolocumab; D000069474:Sofosbuvir